CMS Open Payments · Program Year 2024
Treace Medical Concepts, Inc.
Treace Medical Concepts, Inc. reported $10,523,380.86 across General Payments, Research, and Ownership to 10,486 physicians and teaching hospitals across 10,942 transactions.
- $10.5M
- All-tracks total
- 10,942
- Transactions
- 10,486
- Recipients
- −$1.4M
- General Payments vs PY2023
Treace Medical Concepts, Inc. reported $10,523,380.86 across all CMS Open Payments tracks (General + Research + Ownership) to 10,486 physicians and teaching hospitals in Program Year 2024 - ranking #166 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $10,011,391.43, averaging $1.0K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer treace-medical-concepts-inc Treace Medical Concepts, Inc.
$10.5M · #166/1,925 · 0.1% industry · PY2024
- TOT $10.5M
- RANK #166
- SHARE 0.1%
- TXN 10,942
- RCP 10,486
- CAT 6
- GEN $10.0M
- ΔGEN −$1.4M
- TOP1 15.7%
- PY 2024
Volume peers
Nearest volume peer: Dentsply Sirona Inc ($10.4M)
Treace Medical Concepts, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Treace Medical Concepts, Inc.'s CMS-reported General Payments decreased by $1.4M (−12.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: TREACE MEDICAL CONCEPTS, INC.PY2023: TREACE MEDICAL CONCEPTS, INC.PY2024: TREACE MEDICAL CONCEPTS, INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $11,451,653.67
- PY2024
- $10,011,391.43
What the Data Shows for Treace Medical Concepts, Inc.
Treace Medical Concepts, Inc. ranks #166 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.1% slice of all industry payments reported nationwide for the year. The underlying total is $10,523,380.86 across 10,942 transactions to 10,486 physicians and teaching hospitals - $961.74 per transaction and $1.0K per recipient on average.
"Royalty or License" leads the 6-category general-payment breakdown below at $6.8M (67.9% of General Payments, 120 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Royalty or License" leads Treace Medical Concepts, Inc.'s 6-category general-payment breakdown at $6.8M, 67.9% of the reported total.
Treace Medical Concepts, Inc. reports 6 general-payment categories - the top three are Royalty or License (67.9%), Consulting Fee (25.7%), and Food and Beverage (3.6%). The remaining 3 categories make up 2.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Treace Medical Concepts, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $6.8M | 120 | 67.9% |
| Consulting Fee | $2.6M | 801 | 25.7% |
| Food and Beverage | $364.0K | 8,381 | 3.6% |
| Travel and Lodging | $269.6K | 991 | 2.7% |
| Compensation for Services Other Than Consulting | $2.7K | 171 | 0.0% |
| Education | $1.4K | 22 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $6,504,855.74 (65.0%) of $10,011,391.43 in this company's General Payments records across 3,590 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Treace Medical Concepts, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Paul Dayton
$1,575,615.75 across 98 reported transactions
- 2
William Bret Smith
$1,497,837.34 across 171 reported transactions
- 3
Robert D Santrock
$1,312,127.20 across 142 reported transactions
- 4
Daniel J Hatch
$1,194,515.65 across 75 reported transactions
- 5
William Thomas Decarbo
$924,759.80 across 156 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Treace Medical Concepts, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Treace Medical Concepts, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Treace Medical Concepts, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Astellas Pharma US Inc
Lexicon Pharmaceuticals, Inc.
Sanofi-Aventis U.s. LLC
Exactech, Inc.
Travere Therapeutics, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.